LC
IMVT icon

Lindbrook Capital’s Immunovant IMVT Stock Holding History

Lindbrook Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$5.09K Buy
298
+177
+146% +$3.7K ﹤0.01% 1945
2024
Q4 		$3K Sell
121
-7
-5% -$199 ﹤0.01% 2177
2024
Q3 		$3.65K Hold
128
– – ﹤0.01% 2139
2024
Q2 		$3.38K Buy
128
+73
+133% +$2.08K ﹤0.01% 2168
2024
Q1 		$1.78K Sell
55
-164
-75% -$5.98K ﹤0.01% 2284
2023
Q4 		$9.23K Buy
219
+164
+298% +$6.04K ﹤0.01% 1594
2023
Q3 		$2.11K Buy
55
+34
+162% +$769 ﹤0.01% 2109
2023
Q2 		$398 Hold
21
– – ﹤0.01% 2553
2023
Q1 		$326 Sell
21
-57
-73% -$989 ﹤0.01% 2669
2022
Q4 		$1.39K Sell
78
-21
-21% -$264 ﹤0.01% 2382
2022
Q3 		$1K Buy
99
+42
+74% +$205 ﹤0.01% 2358
2022
Q2 		$0 Sell
57
-232
-80% -$1K ﹤0.01% 2608
2022
Q1 		$2K Buy
+289
New +$1.8K ﹤0.01% 2013
2020
Q3 		– Sell
-500
Closed -$12K – 1792
2020
Q2 		$12K Sell
500
-500
-50% -$10.7K ﹤0.01% 777
2020
Q1 		$16K Buy
+1,000
New +$15K 0.01% 615

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Lindbrook Capital's IMVT Position: Q1 2025 in Review

Lindbrook Capital increased its Immunovant (IMVT) stake by 146% in Q1 2025, buying an estimated $3.7K and bringing the position to 298 shares worth $5.09K. The position accounts for ﹤0.01% of the portfolio, ranked #1945.

Lindbrook Capital first reported a position in IMVT in Q1 2020 and has held it in 15 quarters since. The position peaked at $16K in Q1 2020. 193 funds tracked by Wall St. Rank hold IMVT as of Q1 2025.

  • Lindbrook Capital held 298 shares of Immunovant worth $5.09K as of Q1 2025.
  • Lindbrook Capital bought 177 Immunovant shares in Q1 2025, an estimated $3.7K.
  • Immunovant made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1945 holding.
  • Lindbrook Capital first reported a position in Immunovant in Q1 2020 and has held it in 15 quarters since.
  • Lindbrook Capital's Immunovant position peaked at $16K in Q1 2020.
  • 193 funds tracked by Wall St. Rank held Immunovant as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.